Sandoz wins Health Canada approval for Ozempic generic

Health Canada authorized Sandoz to market a generic version of Novo Nordisk's Ozempic for type 2 diabetes. This marks a regulatory milestone in Canada, potentially increasing access and lowering costs, though market impact is limited to Canada. The move follows similar approvals in other markets, signaling a gradual erosion of Ozempic's exclusivity.